immunocompromis
patient
cancer
hematopoiet
stem
cell
transplant
higher
risk
respiratori
singl
mix
respiratori
virus
frequent
detect
acut
respiratori
defect
innat
adapt
coupl
damag
mucos
membran
frequent
exposur
healthcar
environ
contribut
increas
mortal
respiratori
infect
healthi
children
respiratori
virus
usual
confin
upper
respiratori
tract
immunocompromis
patient
progress
lower
respiratori
tract
frequent
fear
despit
advanc
cancer
therapi
outcom
last
decad
respiratori
viral
infect
complic
frequent
barrier
success
antineoplast
respiratori
infect
major
caus
febril
episod
patient
pediatr
patient
often
initi
antibiot
cover
seriou
bacteri
diseas
lead
unnecessari
increas
exposur
antibiot
potenti
emerg
antibiot
accur
respiratori
viral
diagnosi
earli
access
treatment
improv
outcom
allow
prompt
initi
infect
control
measur
limit
antibiot
molecular
diagnost
assay
respiratori
viru
detect
identif
becom
increasingli
popular
outperform
tradit
viral
detect
method
antigen
detect
cell
assay
term
speed
effici
specif
altogeth
fact
highlight
need
surveil
studi
util
molecular
diagnost
tool
elucid
role
viral
pathogen
respiratori
infect
risk
factor
epidemiolog
studi
respiratori
viral
infect
patient
pediatr
cancer
set
main
purpos
studi
screen
viral
etiolog
agent
associ
risk
factor
complic
respiratori
infect
patient
pediatr
cancer
lebanon
address
joint
need
surveil
studi
use
molecular
diagnost
tool
addit
studi
respiratori
infect
develop
countri
octob
decemb
nasopharyng
swab
collect
cancer
patient
acut
respiratori
tract
infect
arti
children
cancer
center
lebanon
patient
consid
elig
studi
patient
pediatr
cancer
febril
episod
upper
respiratori
tract
symptom
inclus
criteria
follow
age
year
receiv
cancer
treatment
within
last
three
month
fever
within
previou
hour
one
follow
symptom
cough
sore
throat
nasal
congest
rhinorrhea
respiratori
distress
follow
data
obtain
enrol
particip
age
sex
demograph
use
influenza
vaccin
antivir
date
onset
symptom
hospit
admiss
length
stay
medic
chart
review
determin
health
complic
bacteri
infect
absolut
neutrophil
lymphocyt
count
anoth
chart
review
perform
one
month
initi
febril
ill
monitor
potenti
complic
project
approv
institut
review
board
american
univers
beirut
st
jude
children
research
hospit
parent
inform
consent
particip
assent
applic
obtain
nasopharyng
swab
patient
collect
health
care
provid
preserv
viru
transport
media
transport
laboratori
analysi
viral
nucleic
acid
extract
use
purelink
viral
rnadna
mini
kit
invitrogen
carlsbad
ca
kit
appli
biosystem
austin
tx
use
screen
extract
rna
sampl
respiratori
virus
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
influenza
viru
flu
influenza
b
viru
flu
b
rhinoviru
rhv
adenoviru
adv
parainfluenza
virus
parainfluenza
viru
human
coronavirus
sequenc
primer
probe
obtain
center
diseas
control
prevent
cdc
run
perform
presenc
control
ntc
posit
control
target
extract
control
screen
exclud
extract
flu
sampl
subtyp
via
pcr
use
protocol
sampl
subtyp
convent
pcr
follow
gel
electrophoresi
use
primer
specif
g
gene
hypervari
univari
regress
analysi
perform
determin
associ
viral
coinfect
variabl
outcom
includ
demograph
hospitalicu
admiss
lower
respiratori
tract
infect
lrti
clinic
symptom
bronchiti
fever
mechan
ventil
nasal
congest
respiratori
distress
vomit
neutropenia
absolut
neutrophil
count
anc
lymphopenia
absolut
lymphocyt
count
test
odd
ratio
comput
test
associ
categor
variabl
variabl
statist
associ
sever
outcom
univari
model
includ
multivari
logist
regress
use
backward
select
method
signific
level
less
requir
covari
stay
model
odd
ratio
estim
p
valu
test
variabl
monitor
adjust
age
sex
similarli
correl
analysi
variabl
also
includ
correl
coeffici
calcul
measur
strength
relationship
differ
variabl
test
p
valu
consid
signific
statist
analysi
perform
use
sa
softwar
studi
period
febril
episod
record
individu
patient
median
age
patient
year
iqr
year
patient
male
tabl
patient
solid
tumor
liquid
tumor
tabl
preval
respiratori
symptom
popul
cough
rhinorrhea
nasal
congest
sampl
popul
children
admit
hospit
total
respiratori
virus
detect
nasal
swab
obtain
patient
pediatr
cancer
present
fever
patient
n
coinfect
two
virus
n
monoinfect
ie
infect
accord
chart
review
none
patient
coinfect
bacteria
rsv
common
viru
febril
episod
least
one
detect
viru
follow
piv
flu
b
hmpv
preval
virus
monoinfect
hmpv
rsv
rhv
wherea
commonli
detect
virus
coinfect
rsv
flub
figur
respiratori
viral
infect
detect
mainli
winter
season
decemb
march
lesser
extent
spring
figur
sporad
infect
detect
summer
fall
season
sever
respiratori
virus
cocircul
period
influenza
vaccin
rate
rel
low
n
patient
febril
episod
elig
receiv
vaccin
ie
age
month
n
group
n
flu
n
flu
b
vaccin
group
n
influenza
andor
b
infect
n
influenza
b
univari
analysi
use
assess
associ
demograph
variabl
clinic
find
respiratori
virus
arti
tabl
children
younger
year
significantli
higher
risk
develop
respiratori
distress
age
year
p
cl
older
year
p
cl
neutropenia
anc
identifi
risk
factor
hospit
admiss
p
cl
statist
signific
associ
observ
respect
sex
cancer
type
treatment
lymphopenia
antivir
drug
administr
test
variabl
type
cancer
receiv
anticanc
drug
neutropenia
lymphopenia
associ
increas
risk
coinfect
addit
presenc
viral
coinfect
seem
correl
record
clinic
symptom
tabl
next
associ
detect
virus
complic
coinfect
assess
account
small
sampl
size
genotyp
subtyp
viru
group
togeth
eg
influenza
viru
flu
b
rhv
significantli
associ
hospit
admiss
p
cl
wherea
rsv
significantli
associ
lrti
p
cl
nasal
congest
p
hcov
significantli
associ
bronchiol
p
cl
wherea
piv
hmpv
significantli
associ
nasal
congest
p
cl
piv
influenza
viru
rsv
hcov
significantli
associ
coinfect
p
cl
p
cl
p
cl
p
cl
respect
among
rsv
strongest
correl
coinfect
tabl
variabl
analyz
via
multivari
logist
regress
analysi
select
method
backward
elimin
wherebi
p
valu
requir
covari
stay
model
children
age
year
older
year
lower
odd
respect
respiratori
distress
younger
year
p
odd
coinfect
time
greater
p
cl
patient
influenza
without
influenza
furthermor
patient
rsv
infect
time
like
coinfect
p
test
virus
piv
remain
significantli
associ
coinfect
p
cl
infect
rsv
remain
significantli
associ
nasal
congest
p
odd
nasal
congest
cl
time
greater
patient
rsv
without
rsv
infect
adjust
age
sex
estim
signific
chang
correl
analysi
show
rsv
r
p
influenza
viru
r
p
piv
r
p
hcov
r
p
significantli
associ
coinfect
adv
r
p
show
moder
relationship
coinfect
neutropenia
posit
associ
rhv
r
p
piv
neg
associ
r
p
rsv
posit
correl
hcov
r
p
neg
correl
hmpv
r
p
figur
hospit
admiss
neutropenia
significantli
correl
r
p
hospit
admiss
rhv
r
p
diarrhea
significantli
associ
hcov
r
p
rsv
r
p
nasal
congest
also
significantli
correl
rsv
r
p
hcov
r
p
moder
relationship
respiratori
distress
figur
data
reveal
recurr
fever
significantli
relat
previou
rsv
infect
r
p
moder
correl
solid
tumor
r
p
rhinorrhea
posit
relat
previou
rhv
infect
r
p
neg
correl
lymphopenia
r
p
bronchiti
r
p
bacteremia
r
p
significantli
relat
prior
rsv
infect
period
lrti
significantli
associ
rsv
r
p
moder
associ
coinfect
r
p
moreov
posit
correl
observ
bronchiol
previou
hcov
r
p
rsv
infect
r
p
wherea
urti
moder
correl
previou
piv
infect
r
p
figur
studi
period
patient
repeat
febril
episod
often
led
detect
viru
es
associ
first
episod
tabl
median
time
repeat
febril
episod
confirm
viral
infect
day
rang
day
repeat
detect
viru
note
nine
patient
rsv
frequent
detect
repeat
episod
use
pcr
detect
rsv
show
three
pair
sampl
rsva
remain
three
pair
specimen
genotyp
could
determin
least
one
specimen
also
detect
one
case
repeat
episod
flu
b
rhv
adv
hmpv
studi
demonstr
respiratori
virus
lead
caus
acut
respiratori
infect
pediatr
cancer
patient
consid
import
etiolog
febril
neutropenia
hospit
admiss
data
show
viral
infect
associ
febril
episod
patient
pediatr
cancer
detect
respiratori
viral
infect
popul
multipl
implic
includ
persist
infect
diseas
reactiv
find
also
highlight
urgent
need
vaccin
effect
drug
commonli
circul
viral
pathogen
limit
unnecessari
administr
antivir
antibacteri
best
manag
isol
precaut
infect
patient
substanti
subset
studi
popul
coinfect
multipl
virus
find
associ
coinfect
clinic
symptomsoutcom
neutropenia
lymphopenia
patient
consist
find
torr
et
found
differ
clinic
outcom
children
febril
neutropenia
mix
respiratori
viral
infect
monoinfect
similar
find
report
et
found
immunocompet
children
mix
monoinfect
similar
durat
hospit
risk
pediatr
icu
admiss
need
oxygen
howev
studi
immunocompet
children
found
coinfect
associ
lower
respiratori
tract
infect
higher
risk
hospit
admiss
monoinfect
studi
involv
immunocompet
patient
found
evid
increas
sever
result
coinfect
compar
therefor
clinic
implic
respiratori
viral
coinfect
need
investig
studi
investig
respiratori
viral
infect
immunocompromis
children
carri
develop
countri
sweden
respiratori
viral
infect
detect
case
febril
neutropenia
children
mix
similar
rate
respiratori
viral
infect
children
leukemia
mix
malign
report
usa
germani
finland
contrast
spain
respiratori
viral
infect
detect
patient
cancer
viral
infect
mention
studi
rsv
rhv
flu
commonli
detect
studi
group
rsv
preval
viru
follow
piv
flu
b
hmpv
frequent
viru
monoinfect
rsv
detect
predominantli
coinfect
higher
rate
viru
detect
studi
popul
lebanon
could
attribut
use
pcr
higher
number
screen
virus
includ
respiratori
symptom
inclus
criterion
studi
identifi
respiratori
virus
via
one
follow
techniqu
clinic
symptom
serolog
test
viru
cultur
fluoresc
antibodi
detect
pcr
limit
viral
nonetheless
even
compar
studi
util
pcr
diagnost
tool
screen
compar
number
viral
target
patient
cancer
studi
higher
incid
viru
higher
incid
viral
infect
might
attribut
cultur
interact
includ
close
contact
thu
promot
studi
reflect
import
use
molecular
diagnost
assay
clinic
practic
better
diagnosi
improv
patient
import
note
mutat
region
detect
primer
could
result
reduc
detect
rate
pcr
therefor
continu
monitor
circul
viru
strain
updat
detect
primer
captur
novel
variant
strain
necessari
accur
inform
frequenc
respiratori
virus
burden
allow
accur
recommend
priorit
drug
vaccin
develop
instanc
children
receiv
chemotherapi
develop
complic
infect
previou
studi
patient
pediatr
cancer
report
rsv
associ
pneumonia
neutropenia
lead
sever
mucos
common
patient
neutropenia
might
one
predict
factor
sever
respiratori
viral
infect
especi
data
show
rsv
significantli
associ
lrti
fever
bronchiol
nasal
congest
diarrhea
increas
risk
icu
admiss
similar
previous
report
data
suggest
encount
rsv
infect
patient
pediatr
cancer
might
add
diseas
burden
affect
respons
moreov
studi
reveal
high
preval
rsv
coinfect
repeat
infect
patient
pediatr
cancer
highlight
urgent
need
develop
rsv
antivir
vaccin
current
rsv
vaccin
develop
phase
iii
clinic
trial
constitut
step
right
infant
preterm
chronic
ill
rsv
neutral
monoclon
antibodi
includ
palivizumab
effect
prophylaxi
remain
expens
develop
emerg
rsv
variant
resist
palivizumab
concern
highlight
need
therapeut
prophylaxi
util
patient
cancer
especi
highest
risk
infect
studi
younger
children
reduc
potenti
complic
patient
cancer
influenza
infect
usual
accompani
bacteremia
delay
studi
conduct
mendoza
et
show
immunocompromis
children
cancer
hiv
age
year
infect
influenza
requir
hospit
outcom
would
effect
reduc
annual
vaccin
recommend
patient
health
care
provid
studi
infect
influenza
andor
b
detect
case
vaccin
rate
among
children
month
recommend
age
vaccin
febril
episod
consid
low
popul
therefor
emphas
import
attain
univers
vaccin
popul
caregiv
like
improv
patient
outcom
prevent
influenza
infect
durat
shed
frequenc
recurr
viru
detect
thoroughli
investig
immunocompromis
current
studi
patient
repeat
detect
respiratori
virus
subsequ
febril
episod
half
patient
repeat
detect
viru
rsv
common
viru
detect
repeatedli
subsequ
febril
episod
possibl
rule
whether
infect
persist
repeat
infect
studi
includ
patient
febril
episod
develop
rather
monitor
patient
routin
basi
hall
et
report
prolong
rsv
shed
persist
day
martin
et
report
prolong
shed
respiratori
virus
sampl
collect
least
day
apart
virus
involv
prolong
shed
includ
hmpv
rsv
adv
hcov
rhv
piv
studi
soderman
et
suggest
shed
time
flu
hmpv
rsv
piv
limit
viru
clearanc
evid
median
time
day
contrast
rhv
genotyp
detect
subsequ
sampl
day
patient
report
appear
respiratori
symptom
day
fever
onset
indic
possibl
prolong
shed
longitudin
studi
wherebi
patient
screen
weekli
basi
detect
given
viru
confirm
requir
determin
frequenc
repeat
infect
vs
persist
infect
among
children
cancer
impact
patient
outcom
molecular
approach
use
sequenc
sequenti
detect
virus
allow
better
understand
extent
viru
evolut
patient
current
studi
sever
limit
includ
heterogen
cancer
type
studi
popul
absenc
control
group
patient
asymptomat
cancer
anoth
limit
lack
sampl
monitor
statu
detect
respiratori
viru
differenti
prolong
vs
persist
shed
moreov
human
bocaviru
enterovirus
analyz
could
increas
overal
detect
rate
despit
mention
limit
screen
respiratori
virus
relat
clinic
manifest
great
import
especi
scarc
studi
popul
particularli
develop
countri
guid
better
patient
manag
develop
infect
control
measur
respiratori
infect
lead
seriou
complic
might
becom
particularli
context
weaken
immun
system
patient
cancer
studi
investig
respiratori
infect
patient
cancer
especi
children
studi
detect
high
incid
respiratori
viral
infect
among
children
cancer
lebanon
via
pcr
result
demonstr
use
pcr
diagnosi
therefor
guid
proper
clinic
manag
infect
control
prevent
respiratori
viral
infect
immunocompromis
patient
includ
cancer
critic
protect
patient
especi
given
absenc
effect
vaccin
antivir
drug
virus
project
support
children
infect
defens
center
fund
alsac
american
univers
beirut
faculti
medicin
seed
fund
author
declar
conflict
interest
